Tim Lennon

Tim Lennon is publicly associated with Summa Therapeutics, a Cambridge, Massachusetts medical device company founded in 2013. LinkedIn lists him in Los Angeles and identifies Summa Therapeutics as his current company; SignalHire lists him as Co-Founder and Board Member, with 30 years of experience and a California location.

Summa Therapeutics develops catheter technologies for vascular procedures, particularly below-the-knee interventions for patients with peripheral arterial disease. The company describes itself as an early commercial-stage medical device company focused on vascular patient care and says its mission is “to help save limbs and improve lives.”

Lennon’s LinkedIn profile lists University of the Pacific as his education, attended from 1992 to 1996, with NCAA Division I men’s volleyball participation. Public sources did not verify the provided Libero Holdings title, email, phone number, check size, or angel-investor portfolio.

• Publicly verifiable sources did not surface a stated angel-investing thesis from Lennon.
• His strongest verified operating focus is medtech, especially vascular devices for peripheral arterial disease and below-the-knee revascularization.
• Summa’s product focus suggests interest in medical devices that reduce procedure complexity, catheter exchanges, radiation exposure, and contrast use.
• Summa’s site states that its Finesse BTK Multicath is designed to combine crossing, injection, and angioplasty functions in one catheter.